ELIZABETH FERNANDES, M.D.; F. MICHAEL MELEWICZ, M.D.
To the editor: The newly available histamine (H2) receptor antagonist, ranitidine hydrochloride (Zantac; Glaxo Inc. , Fort Lauderdale, Florida) has been approved for short-term treatment of duodenal ulcer. Ranitidine is four to eight times more potent than Cimetidine for inhibiting gastric acid secretions (1). As the use of ranitidine increases, reports of its interaction with other drugs such as warfarin and metoprolol are appearing (2). We report a case of theophylline toxicity induced by toxic elevation of serum theophylline levels after initiation of ranitidine therapy.
A 75-year-old man with a history of chronic obstructive pulmonary disease with bronchospasm, peptic ulcer
Learn more about subscription options.
Register Now for a free account.
FERNANDES E, MELEWICZ FM. Ranitidine and Theophylline. Ann Intern Med. 1984;100:459. doi: 10.7326/0003-4819-100-3-459_1
Download citation file:
Published: Ann Intern Med. 1984;100(3):459.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only